Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain; Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la salut, Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain.
Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Nutrigenomics Research Group, Spain.
Clin Nutr. 2022 Feb;41(2):489-499. doi: 10.1016/j.clnu.2021.11.033. Epub 2021 Dec 1.
BACKGROUND & AIMS: Whether bioactive lysophospholipids (lyso-PLs) and trimethylamine-N-oxide (TMAO) serve as non-invasive biomarkers in early human hypercholesterolemia (HC) is unknown. This study aimed to assess whether serum lyso-PLs and plasma TMAO may be suitable susceptibility/risk biomarkers of HC in humans. Secondarily, we aimed to evaluate the relationships between targeted metabolites, diet composition and circulating liver transaminases, and verify these results in hamsters.
A targeted metabolomics and lipidomics approach determined plasma TMAO and serum lysophosphatidylcholines (lyso-PCs) and lysophosphatidylethanolamines (lyso-PEs) in low (L-LDL-c) and moderate to high (MH-LDL-c) LDL-cholesterol subjects. Additionally, the relationships between targeted metabolites, liver transaminases and diet, particularly fatty acid intake, were tested. In parallel, plasma and liver lyso-PL profiles were studied in 16 hamsters fed a moderate high-fat (HFD) or low-fat (LFD) diet for 30 days.
Predictive models identified lyso-PC15:0 and lyso-PE18:2 as the most discriminant lyso-PLs among groups. In MH-LDL-c (n = 48), LDL-cholesterol and saturated FAs were positively associated with lyso-PC15:0, whereas in L-LDL-c (n = 70), LDL-cholesterol and polyunsaturated fatty acids (PUFAs) were negatively and positively related to lyso-PE18:2, respectively. Interestingly, in MH-LDL-c, the lower lyso-PE 18:2 concentrations were indicative of higher LDL-cholesterol levels. Intrahepatic accumulation of lyso-PLs-containing essential n-6 PUFAs, including lyso-PE18:2, were higher in HFD-fed hamsters than LFD-fed hamsters.
Overall, results revealed a possible hepatic adaptive mechanism to counteract diet-induced steatosis in animal and hypercholesterolemia progression in humans. In particular, low serum lyso-PE18:2 suggests a suitable susceptibility/risk biomarker of HC in humans.
生物活性溶血磷脂(lyso-PL)和三甲胺 N-氧化物(TMAO)是否可作为人类早期高胆固醇血症(HC)的非侵入性生物标志物尚不清楚。本研究旨在评估血清 lyso-PL 和血浆 TMAO 是否可作为人类 HC 的易感性/风险生物标志物。其次,我们旨在评估靶向代谢物、饮食组成和循环肝转氨酶之间的关系,并在仓鼠中验证这些结果。
采用靶向代谢组学和脂质组学方法测定低(L-LDL-c)和中至高(MH-LDL-c)LDL-胆固醇受试者的血浆 TMAO 和血清溶血磷脂酰胆碱(lyso-PC)和溶血磷脂酰乙醇胺(lyso-PE)。此外,还测试了靶向代谢物、肝转氨酶与饮食(特别是脂肪酸摄入)之间的关系。同时,在喂食中等高脂肪(HFD)或低脂肪(LFD)饮食 30 天的 16 只仓鼠中研究了血浆和肝脏 lyso-PL 谱。
预测模型确定 lyso-PC15:0 和 lyso-PE18:2 是组间最具鉴别力的 lyso-PL。在 MH-LDL-c(n=48)中,LDL-胆固醇和饱和 FA 与 lyso-PC15:0 呈正相关,而在 L-LDL-c(n=70)中,LDL-胆固醇和多不饱和脂肪酸(PUFA)分别与 lyso-PE18:2 呈负相关和正相关。有趣的是,在 MH-LDL-c 中,较低的 lyso-PE18:2 浓度提示 LDL-胆固醇水平较高。富含必需 n-6 多不饱和脂肪酸(包括 lyso-PE18:2)的肝内 lyso-PL 蓄积在 HFD 喂养的仓鼠中高于 LFD 喂养的仓鼠。
总体而言,结果显示动物中可能存在一种肝脏适应机制,以抵消饮食诱导的脂肪肝和人类中高胆固醇血症的进展。特别是,血清 lyso-PE18:2 水平较低提示人类 HC 的易感性/风险生物标志物较合适。